Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.71)
# 828
Out of 5,124 analysts
108
Total ratings
49.23%
Success rate
9.24%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $216 → $230 | $175.07 | +31.38% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $2.00 | +100.00% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $8.13 | +35.30% | 2 | Oct 30, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Overweight | $6 | $4.14 | +44.93% | 1 | Sep 22, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $2.56 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $502.71 | +4.43% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $60.07 | +49.83% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $468.38 | +2.48% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $54.42 | +1.07% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $121.36 | -34.08% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $13.53 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $776.54 | +30.71% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $330.17 | +22.66% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $406.40 | -45.87% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $15.44 | -35.23% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.62 | +15.66% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $58.19 | +23.73% | 1 | Apr 13, 2023 |
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $175.07
Upside: +31.38%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $2.00
Upside: +100.00%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $8.13
Upside: +35.30%
CytomX Therapeutics
Sep 22, 2025
Initiates: Overweight
Price Target: $6
Current: $4.14
Upside: +44.93%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.56
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $502.71
Upside: +4.43%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $60.07
Upside: +49.83%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $468.38
Upside: +2.48%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $54.42
Upside: +1.07%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $121.36
Upside: -34.08%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $13.53
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $776.54
Upside: +30.71%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $330.17
Upside: +22.66%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $406.40
Upside: -45.87%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $15.44
Upside: -35.23%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.62
Upside: +15.66%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $58.19
Upside: +23.73%